MARKET

CTOR

CTOR

Citius Oncology, Inc.
NASDAQ
0.7500
-0.0030
-0.40%
Opening 10:12 08/10 EDT
OPEN
0.7600
PREV CLOSE
0.7530
HIGH
0.7600
LOW
0.7401
VOLUME
14.13K
TURNOVER
--
52 WEEK HIGH
2.250
52 WEEK LOW
0.4912
MARKET CAP
69.74M
P/E (TTM)
-1.6026
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CTOR last week (0803-0807)?
Weekly Report · 4h ago
Buy Rating Reaffirmed on Lymphir’s Growing Commercial Momentum and CTCL Market Upside; $4 Price Target Maintained
TipRanks · 1d ago
Citius Oncology reports strong LYMPHIR commercial momentum
TipRanks · 5d ago
Citius Oncology Reports 78% QoQ Growth In New Institutional Accounts Ordering LYMPHIR; Near‑Universal Payer Coverage Expands Market Access With Initial CTCL Market Exceeding $400M
Benzinga · 5d ago
Weekly Report: what happened at CTOR last week (0727-0731)?
Weekly Report · 08/03 10:16
Weekly Report: what happened at CTOR last week (0720-0724)?
Weekly Report · 07/27 10:20
Citius Oncology provides update on commercial launch of Lymphir
TipRanks · 07/21 13:25
Citius Oncology Expands LYMPHIR Launch Team Nationwide Ahead Of Full U.S. Deployment In August
Benzinga · 07/21 13:19
More
About CTOR
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.

Webull offers Citius Oncology Inc stock information, including NASDAQ: CTOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTOR stock methods without spending real money on the virtual paper trading platform.